- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Interventions
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 781,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 550,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Metastatic, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Glipizide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Healthy
- Interventions
- 5 mg/500 mg METAGLIP™ Tablets, 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 2
- States / cities
- East Grand Forks, Minnesota • Fargo, North Dakota
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide, Glipizide
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
- Interventions
- Canakinumab 150 mg, Placebo to Canakinumab
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
- Conditions
- Healthy
- Interventions
- Glipizide and Metformin HCl Tablets 5 mg/500 mg, Metaglip® Tablets 5 mg/500 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Human Gastrointestinal Physiology Data
- Interventions
- Glucotrol XL 5Mg Extended-Release Tablet, Glipizide ER 5 MG 24 HR Extended Release Oral Tablet, Rifaximin 200Mg Tab, 13C6-Glipizide
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 714,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glipizide, Metformin, Oral Glucose Tolerance Test
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,033 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2025
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Metformin, Glipizide 5 MG
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin, Glipizide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 65 Years to 90 Years
- Enrollment
- 441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 36
- States / cities
- Alexander City, Alabama • Foothill Ranch, California • Huntington Park, California + 33 more
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Diseases
- Interventions
- SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
- Drug
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 241,981 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Pasadena, California • Pleasanton, California • Honolulu, Hawaii + 3 more
- Conditions
- Healthy
- Interventions
- Glipizide and Metformin HCl Tablets 5 mg/500 mg, Metaglip® Tablets 5 mg/500 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Type 2 Diabetes
- Interventions
- Glipizide, Glipizide and Glargine
- Drug
- Lead sponsor
- Cook County Health
- Government
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus Type 2, Hyperglycemia
- Interventions
- Glipizide XL, Saxagliptin + Metformin XR, Metformin XR
- Drug
- Lead sponsor
- Cook County Health
- Government
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Atherosclerosis
- Interventions
- Glipizide, rosiglitazone maleate
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
- Conditions
- Obesity and Type 2 Diabetes
- Interventions
- 10 mg glipizide ingestion
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Healthy
- Interventions
- 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets, 5 mg/500 mg METAGLIP™ Tablets
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 2
- States / cities
- East Grand Forks, Minnesota • Fargo, North Dakota
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Alogliptin, Metformin, Glipizide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,639 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 94
- States / cities
- Montgomery, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 91 more
- Conditions
- Chronic Kidney Diseases, Type 2 Diabetes
- Interventions
- Linagliptin, Glipizide
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington